Literature DB >> 29523556

Prevalent Cardiovascular Disease Events and T1 Mapping Defined Hepatic Fibrosis.

Michelle T Long1, Emelia J Benjamin2.   

Abstract

Entities:  

Keywords:  Editorials; insulin resistance; lipogenesis; non-alcoholic fatty liver disease; triglycerides

Mesh：

Year:  2018        PMID： 29523556      PMCID： PMC5846198          DOI： 10.1161/CIRCIMAGING.118.007553

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN： 1941-9651            Impact factor:   7.792


× No keyword cloud information.
  33 in total

1.  Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis.

Authors:  Peter J Meffert; Sebastian E Baumeister; Markus M Lerch; Julia Mayerle; Wolfgang Kratzer; Henry Völzke
Journal:  Am J Gastroenterol       Date:  2014-06-24       Impact factor: 10.864

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 3.  Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions.

Authors:  Rohit Loomba
Journal:  J Hepatol       Date:  2017-12-02       Impact factor: 25.083

Review 4.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

Authors:  Kenneth Cusi
Journal:  Gastroenterology       Date:  2012-02-08       Impact factor: 22.682

5.  Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis.

Authors:  Fernando Bril; Romina Lomonaco; Beverly Orsak; Carolina Ortiz-Lopez; Amy Webb; Fermin Tio; Joan Hecht; Kenneth Cusi
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

6.  A model for hepatic fibrosis: the competing effects of cell loss and iron on shortened modified Look-Locker inversion recovery T1 (shMOLLI-T1 ) in the liver.

Authors:  Elizabeth M Tunnicliffe; Rajarshi Banerjee; Michael Pavlides; Stefan Neubauer; Matthew D Robson
Journal:  J Magn Reson Imaging       Date:  2016-07-23       Impact factor: 4.813

7.  Double contrast-enhanced MRI of viral hepatitis-induced cirrhosis: correlation of gross morphological signs with hepatic fibrosis.

Authors:  J S Yu; J H Shim; J J Chung; J H Kim; K W Kim
Journal:  Br J Radiol       Date:  2009-06-08       Impact factor: 3.039

8.  Assessment of liver fibrosis by variable flip angle T1 mapping at 3.0T.

Authors:  Zhiming Li; Jihong Sun; Xi Hu; Ning Huang; Guocan Han; Lumin Chen; Yurong Zhou; Weixian Bai; Xiaoming Yang
Journal:  J Magn Reson Imaging       Date:  2015-08-12       Impact factor: 4.813

Review 9.  MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.

Authors:  Parambir S Dulai; Claude B Sirlin; Rohit Loomba
Journal:  J Hepatol       Date:  2016-06-14       Impact factor: 25.083

10.  Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.

Authors:  Michael Pavlides; Rajarshi Banerjee; Joanne Sellwood; Catherine J Kelly; Matthew D Robson; Jonathan C Booth; Jane Collier; Stefan Neubauer; Eleanor Barnes
Journal:  J Hepatol       Date:  2015-11-10       Impact factor: 25.083
View more
  1 in total

1.  Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography.

Authors:  Constanze Bardach; Leonie Morski; Katharina Mascherbauer; Carolina Donà; Matthias Koschutnik; Kseniya Halavina; Christian Nitsche; Dietrich Beitzke; Christian Loewe; Elisabeth Waldmann; Michael Trauner; Julia Mascherbauer; Christian Hengstenberg; Andreas Kammerlander
Journal:  J Clin Med       Date:  2022-05-19       Impact factor: 4.964
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.